Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

LAVA Therapeutics Highlights Encouraging Clinical Updates on Lead Cancer Program

  • LAVA Therapeutics N.V. (NASDAQ:LVTX) hosted a clinical update call focused on initial Phase 1/2a data for LAVA-051 in patients with chronic lymphocytic leukemia (CLL) and multiple myeloma (MM) at the American Society of Clinical Oncology and European Hematology Association meetings.
  • "Although preliminary, these data support our view of LAVA-051 as a promising candidate that has the potential to overcome challenges of existing T-cell approaches, which frequently show cytokine release syndrome very close to their efficacious dose," said Arnon Kater, LAVA-051 clinical trial investigator.
  • Related: LAVA Therapeutics Shares Interim LAVA-051 Data From Early-Stage Cancer Trial.
  • The early clinical data from the first four cohorts demonstrate early signals of potential anti-tumor activity in CLL and MM patients and an attractive safety profile, Kater added.
  • Notably, the pharmacodynamic determinations gathered from the patients in the early clinical study reflect the mechanism of action of LAVA-051, he added.
  • LAVA-051 is a humanized Gammabody designed to activate both Vγ9Vδ2 (Vgamma9 Vdelta2) T cells and type 1 NKT cells to kill CD1d-expressing tumor cells. 
  • Price Action: LVTX shares closed at $2.78 on Thursday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.